公开(公告)号：US11639529B2

公开(公告)日：2023-05-02

申请号：US16594718

申请日：2019-10-07

Applicant: Quest Diagnostics Investments LLC

Inventor： Heather R. Sanders ,  Maher Albitar ,  Aurelia Meloni-Ehrig

IPC: C12Q1/6886 ,  C07K16/40 ,  C12Q1/48

Abstract: The present disclosure relates to methods for the diagnosis and evaluation of neoplastic disorders, particularly non-small cell lung cancer. Assays are described in which patient test samples are analyzed for the presence of one or more specific EML4-ALK fusion genes associated with neoplastic disorders.

公开(公告)号：US20200181718A1

公开(公告)日：2020-06-11

申请号：US16707661

申请日：2019-12-09

Applicant: Quest Diagnostics Investments LLC

Inventor： Heather R. Sanders ,  Maher Albitar ,  Aurelia Meloni-Ehrig

IPC: C12Q1/6886 ,  C12Q1/6858 ,  C12Q1/6851 ,  C12Q1/6827 ,  C12Q1/6809 ,  G16B25/00

Abstract: Described herein are methods, compositions and kits directed to the detection of gene dysregulations such as those arising from gene fusions and/or chromosomal abnormalities, e.g., translocations, insertions, inversions and deletions. Samples containing dysregulated gene(s) of interest may show independent expression patterns for the 5′ and 3′ regions of the gene. The methods, compositions and kits are useful for detecting mutations that cause the differential expression of a 5′ portion of a target gene relative to the 3′ region of the target gene.

公开(公告)号：US12018402B2

公开(公告)日：2024-06-25

申请号：US16325856

申请日：2017-08-17

Applicant: Quest Diagnostics Investments LLC

Inventor： Michael J. McPhaul ,  Heather R. Sanders

IPC: C40B30/04 ,  A61K31/03 ,  A61K31/48 ,  A61K31/567 ,  A61K31/4174 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/451 ,  A61K31/496 ,  A61K31/506 ,  C12Q1/6806 ,  C12Q1/6886

CPC classification number: C40B30/04 ,  A61K31/03 ,  A61K31/48 ,  A61K31/567 ,  A61K31/4174 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/451 ,  A61K31/496 ,  A61K31/506 ,  C12Q1/6806 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156

Abstract: The present technology is related to methods for detecting genetic alterations underlying intracranial neoplasms such as pituitary adenomas, meningiomas, and craniopharyngiomas. The methods disclosed herein are useful in determining whether a patient harboring an intracranial tumor will benefit from or is predicted to be responsive to treatment with an individual therapeutic agent or a specific combination of therapeutic agents. Kits for use in practicing the methods are also provided.

公开(公告)号：US11965212B2

公开(公告)日：2024-04-23

申请号：US17500858

申请日：2021-10-13

Applicant: Quest Diagnostics Investments LLC

Inventor： Heather R. Sanders ,  Kevin Z. Qu ,  Charles M. Strom ,  Richard A. Bender

IPC: C12Q1/68 ,  C12Q1/6806 ,  C12Q1/6886

CPC classification number: C12Q1/6886 ,  C12Q1/6806 ,  C12Q2600/118 ,  C12Q2600/156 ,  C12Q2600/16 ,  C12Q1/6886 ,  C12Q2531/113 ,  C12Q2521/301

Abstract: Provided herein are methods and compositions for detection of a nucleic acid target in a sample. The methods and compositions use primer directed amplification in conjunction with nucleic acid fragmentation. The methods have high sensitivity even in the presence of a large amount of non-target nucleic acid. Also provided are oligonucleotides and kits useful in the method. Exemplary nucleic acid targets are those with mutant gene sequence such as mutant sequence of the EGFR, APC, TMPRSS2, ERG and ETV1 genes.

公开(公告)号：US11667909B2

公开(公告)日：2023-06-06

申请号：US16887079

申请日：2020-05-29

Applicant: Quest Diagnostics Investments LLC

Inventor： Heather R. Sanders

IPC: C12P19/34 ,  C12N15/10 ,  C12Q1/6806 ,  C12Q1/6886

CPC classification number: C12N15/1017 ,  C12Q1/6806 ,  C12Q1/6886 ,  C12Q2600/158 ,  C12Q1/6806 ,  C12Q2527/125

Abstract: The invention provides methods for isolating RNA from whole urine and urine fractions for the diagnosis of prostate cancer and/or benign prostate hyperplasia. An exemplary method for diagnosing prostate cancer in an individual, said method comprises: (a) determining the amount of RNA encoding one or more diagnostic genes in the soluble urine fraction of a urine sample obtained from said individual; (b) comparing the amount of said RNA to a reference value for said one or more diagnostic genes, wherein said reference value is derived from the amount of RNA encoding said one or more diagnostic genes in one or more individuals that do not have prostate cancer; and (c) diagnosing said individual as having prostate cancer when the amount of said RNA is greater than said reference value.

公开(公告)号：US10669536B2

公开(公告)日：2020-06-02

申请号：US15952452

申请日：2018-04-13

Applicant: Quest Diagnostics Investments LLC

Inventor： Heather R. Sanders

IPC: C12P19/34 ,  C12N15/10 ,  C12Q1/6806 ,  C12Q1/6886

Abstract: The invention provides methods for isolating RNA from whole urine and urine fractions for the diagnosis of prostate cancer and/or benign prostate hyperplasia. An exemplary method for diagnosing prostate cancer in an individual, said method comprises: (a) determining the amount of RNA encoding one or more diagnostic genes in the soluble urine fraction of a urine sample obtained from said individual; (b) comparing the amount of said RNA to a reference value for said one or more diagnostic genes, wherein said reference value is derived from the amount of RNA encoding said one or more diagnostic genes in one or more individuals that do not have prostate cancer; and (c) diagnosing said individual as having prostate cancer when the amount of said RNA is greater than said reference value.

公开(公告)号：US20230416835A1

公开(公告)日：2023-12-28

申请号：US18141862

申请日：2023-05-01

Applicant: Quest Diagnostics Investments LLC

Inventor： Heather R. Sanders ,  Maher Albitar ,  Aurelia Meloni-Ehrig

IPC: C12Q1/6886

CPC classification number: C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/156 ,  C12Q2600/16 ,  C07K16/40

Abstract: The present disclosure relates to methods for the diagnosis and evaluation of neoplastic disorders, particularly non-small cell lung cancer. Assays are described in which patient test samples are analyzed for the presence of one or more specific EML4-ALK fusion genes associated with neoplastic disorders.

公开(公告)号：US11155877B2

公开(公告)日：2021-10-26

申请号：US16165400

申请日：2018-10-19

Applicant: Quest Diagnostics Investments LLC

Inventor： Heather R. Sanders ,  Kevin Z. Qu ,  Charles M. Strom ,  Richard A. Bender

IPC: C12Q1/68 ,  C12Q1/6886 ,  C12Q1/6806

Abstract: Provided herein are methods and compositions for detection of a nucleic acid target in a sample. The methods and compositions use primer directed amplification in conjunction with nucleic acid fragmentation. The methods have high sensitivity even in the presence of a large amount of non-target nucleic acid. Also provided are oligonucleotides and kits useful in the method. Exemplary nucleic acid targets are those with mutant gene sequence such as mutant sequence of the EGFR, APC, TMPRSS2, ERG and ETV1 genes.

公开(公告)号：US20190100808A1

公开(公告)日：2019-04-04

申请号：US16165400

申请日：2018-10-19

Applicant: Quest Diagnostics Investments LLC

Inventor： Heather R. Sanders ,  Kevin Z. Qu ,  Charles M. Strom ,  Richard A. Bender

IPC: C12Q1/6886 ,  C12Q1/6806

Abstract: Provided herein are methods and compositions for detection of a nucleic acid target in a sample. The methods and compositions use primer directed amplification in conjunction with nucleic acid fragmentation. The methods have high sensitivity even in the presence of a large amount of non-target nucleic acid. Also provided are oligonucleotides and kits useful in the method. Exemplary nucleic acid targets are those with mutant gene sequence such as mutant sequence of the EGFR, APC, TMPRSS2, ERG and ETV1 genes.

公开(公告)号：US20190093176A1

公开(公告)日：2019-03-28

申请号：US16153108

申请日：2018-10-05

Applicant: Quest Diagnostics Investments LLC

Inventor： Heather R. Sanders ,  Maher Albitar ,  Aurelia Meloni-Ehrig

IPC: C12Q1/6886 ,  G06F19/20 ,  C12Q1/6858 ,  C12Q1/6851 ,  C12Q1/6809 ,  C12Q1/6827

Abstract: Described herein are methods, compositions and kits directed to the detection of gene dysregulations such as those arising from gene fusions and/or chromosomal abnormalities, e.g., translocations, insertions, inversions and deletions. Samples containing dysregulated gene(s) of interest may show independent expression patterns for the 5′ and 3′ regions of the gene. The methods, compositions and kits are useful for detecting mutations that cause the differential expression of a 5′ portion of a target gene relative to the 3′ region of the target gene.